• In Taiwan, eribulin is indicated for the treatment of patients with locally advanced breast cancer or MBC who have progressed following at least two prior chemotherapeutic regimens for the advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients are not suitable for these treatments.
[9] Health State Utilities:
RESULTS
• As described in the earlier section, health state utilities were obtained from a study specific to the population of Taiwan. The health state utilities and disutilities used in the model were as follows: • OS based on Gamma extrapolation was 17.26 months in eribulin group versus 14.39 months in TPC group for a difference of 2.87 months.
• Mean time without progressive disease was 4.68 months for eribulin and 3.96 months for TPC for a difference of 0.72 months.
• The Quality Adjusted Life Years were 0.83 in the eribulin group compared to 0.70 in TPC group for a mean incremental improvement of 0.13 years.
• Treatment costs were €9,664 for eribulin and €3,119 for TPC for a difference of €6,545.
• In base-case analysis, the ICER with discounting was €50,080.
• Survival time was most sensitive variables on the ICER in this CEA.
OBJECTIVE
• The objective of this study was to estimate Incremental Cost-Effectiveness Ratio(ICER) of utilizing eribulin against Treatment of Physician's Choice (TPC) for third line treatment of Metastatic Breast Cancer (MBC) in Taiwan.
METHODS
• A five-year partitioned survival cost-effectiveness analysis(CEA) with a Quality-adjusted Time Without Symptoms and Toxicity(Q-TWiST) as the effectiveness measure was developed.
• Drugs included in TPC arm were based on the data from EMBRACE Clinical Trial and MBC treatment algorithm in Taiwan the data for which was based on a Taiwanese Ad-board study (Data on File)
• The drugs in the TPC arm were :
o Paclitaxel • Costs included in the model were drugs & administration, post-treatment resource use, toxicity management and indirect treatment costs.
• Cost effectiveness was evaluated using the Gamma distribution for Overall Survival(OS), Weibull for Progression Free Survival(PFS), response duration and, toxicity time.
• Health state utilities were applied to each component and aggregated. 
Utility Assessments
• The health state utilities were assessed using a quality of life study designed for women in Taiwan.
• The study comprised of a visual analogue scale, a standard gamble questionnaire and a quality of life survey comprising of five domains i.e. Physical well being, Emotional well being, Functional well being, social well being and additional concerns • The administration method and techniques for these instruments were also based on the guidelines developed the same group [11]
• Data was collected for 30 Taiwanese women. 3 suffering from Brest Cancer, one suffering from other cancer. [Data on File]
• The disutilities associated with adverse events were obtained from the MBC health state utility study conducted by Lloyd et.al.
[12] 
LIMITATIONS
• The comparator arm comprised of five drugs based on the MBC treatment algorithm in Taiwan. In the clinical trial, the TPC arm comprised of more drugs. Although the five drugs used in the model comprised of majority of market share of the drugs used in the analysis, using efficacy data from the trial directly may have led to some selection bias in the results.
• The data on healthcare resource utilization was sourced from Physician Opinion which may also have led to some bias in the results of economic analysis.
• The health state utility data was not collected in the EMBRACE trial. It was obtained through a local vignette study and literature. This may have further introduced a small bias in the study results 
RESULTS

CONCLUSION
• With an ICER of €50,080 compared to TPC, eribulin was found to be cost-effective in third and later line MBC population in Taiwan.
• Given the limited number of effective therapeutic options available to these patients, eribulin represents a valid option for optimizing treatment pathways.
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